Due to the concerning rise in sexually transmitted infection (STIs) transmission across Europe, the European Centre for Disease Prevention and Control (ECDC) is urging everyone to keep informed and practice safer sex as they leave for holidays, festivals, and travel this summer season.
In 2024 and as of 30 of April, approximately 240 000 CHIKVD cases and over 90 deaths have been reported worldwide. A total of 18 countries reported CHIKVD cases from the Americas (11), Asia (6), and Africa (1).
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 25-31 May 2024 and includes updates on avian influenza, respiratory viruses, invasive meningococcal disease, mass gatherings for Hajj in Saudi Arabia, cholera, chikungunya, dengue, and poliomyelitis.
Every month ECDC provides detailed epidemiological overview of the worldwide transmission of chikungunya in its weekly threat report (Communicable Diseases Threat Report).
On 31 May 2024, the European Medicines Agency (EMA) published the Committee for Medicinal Products for Human Use (CHMP) reflection paper on Creutzfeldt-Jakob disease (CJD) and plasma-derived and urine-derived medicinal products.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 18-25 May 2024 and includes updates on respiratory virus epidemiology in the EU/EEA, influenza, avian influenza, and cholera.
In 2022, 27 European Union/European Economic Area (EU/EEA) countries reported 731 echinococcosis cases. Of these, 299 (41%) cases were reported as Echinococcus granulosus sensu lato, 185 (25%) as E. multilocularis and 247 (34%) as an unknown species.
In 2022, 28 European Union/European Economic Area (EU/EEA) countries reported 39 cases of trichinellosis, which represented a 49% decrease compared with 2021.
As the summer season is approaching, ECDC is hosting an online scientific seminar to raise awareness of vibriosis and it associated risks. The main target audience is the European Food- and Waterborne Diseases and Zoonoses Network but registration is open for anyone with an interest in the topic.
Influenza, SARS-CoV-2 and RSV activity in EU/EEA Member States continue to decrease or remain stable at low levels. Cases, including severe infections, can still occur and it therefore remains essential to continue testing patients presenting with severe acute respiratory symptoms in order to guide treatment and inform epidemiological assessments.